Depression that doesn’t respond to conventional treatments is a serious problem for all who are affected, and poses unique risks for those over 60. Late-life depression is often complicated by…
Read More
On September 6, 2022, the U.S. Food and Drug Administration cleared the way for marketing of a rapid-acting brain-stimulation approach for major depressive disorder pioneered by Nolan Williams, M.D…
Read More
A research team led in part by two BBRF grantees has reported initial success in using a novel, highly personalized, and technologically advanced treatment approach to relieve symptoms in a single…
Read More
Newly reported results of a small phase 2 clinical trial indicate the potential utility of using nitrous oxide treatments in patients with severe major depression that has not responded to other…
Read More
Imagine a new treatment for people with major depression who have not responded to existing treatments—one that acts rapidly and helps a much larger fraction of such patients than any current…
Read More
